Company
Headquarters: Oulu, Finland
Employees: 21
€9.2 Million
EUR as of Jan. 1, 2024
US$10.1 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $192.67 B |
| Stryker Corporation | $113.24 B |
| Medtronic | $111.60 B |
| Boston Scientific Corporation | $85.22 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
BBS-Bioactive Bone Substitutes Plc, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland. The company offers ARTEBON, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins used primarily for the treatment of bone defects and healing problems in extremities, such as foot and ankle. BBS-Bioactive Bone Substitutes Plc was incorporated in 1991 and is headquartered in Oulu, Finland.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
BBS-Bioactive Bone Substitutes Oyj has the following listings and related stock indices.
Stock: OMXH: BONEH wb_incandescent
Stock: OMX: BONES wb_incandescent